Largest one day declines
The 50 largest one day percentage moves lower recorded at the latest close. The largest moves were GENB at −20.8% and SYRE at −12.8%. By size, the list splits into 4 mega cap, 9 large cap and 37 mid cap listings.
Switch view
All stocks50 of 23,178 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1D return | 1Y return |
|---|---|---|---|---|---|
| GENB | Generate Biomedicines, Inc. | $2.07B | Mid cap | −20.80% | +27.59% |
| SYRE | Spyre Therapeutics, Inc. | $8.13B | Mid cap | −12.81% | +446.12% |
| HIMS | Hims & Hers Health, Inc. | $6.96B | Mid cap | −6.05% | −32.22% |
| MRNA | Moderna, Inc. | $59.75B | Large cap | −5.77% | +496.25% |
| RLAY | Relay Therapeutics, Inc. | $4.26B | Mid cap | −5.40% | +445.10% |
| TLX | Telix Pharmaceuticals Limited | $3.77B | Mid cap | −4.79% | −8.02% |
| BFLY | Butterfly Network, Inc. | $2.30B | Mid cap | −4.42% | +450.32% |
| IOVA | Iovance Biotherapeutics, Inc. | $3.66B | Mid cap | −4.27% | +233.88% |
| CAI | Caris Life Sciences, Inc. | $7.58B | Mid cap | −4.25% | −29.83% |
| JAZZ | Jazz Pharmaceuticals plc | $16.89B | Large cap | −4.20% | +100.35% |
| BLLN | BillionToOne, Inc. | $4.54B | Mid cap | −3.85% | −11.68% |
| LLY | Eli Lilly and Company | $1.06T | Mega cap | −3.59% | +62.80% |
| GRAL | GRAIL, Inc. | $3.55B | Mid cap | −3.57% | +136.66% |
| BSX | Boston Scientific Corporation | $69.81B | Large cap | −3.39% | −54.50% |
| BHC | Bausch Health Companies Inc. | $2.43B | Mid cap | −3.27% | −10.45% |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.07B | Mid cap | −3.24% | +11.33% |
| IRTC | iRhythm Holdings, Inc. | $4.06B | Mid cap | −3.20% | −29.83% |
| BLTE | Belite Bio, Inc | $6.31B | Mid cap | −3.09% | +144.07% |
| CORT | Corcept Therapeutics Incorporated | $12.95B | Large cap | −3.05% | +71.81% |
| NVO | Novo Nordisk A/S | $208.63B | Mega cap | −3.02% | −13.32% |
| XNCR | Xencor, Inc. Common Stock | $2.11B | Mid cap | −2.94% | +254.61% |
| LEGN | Legend Biotech Corporation | $4.02B | Mid cap | −2.91% | −40.44% |
| CRSP | CRISPR Therapeutics AG | $5.73B | Mid cap | −2.74% | +10.65% |
| BEAM | Beam Therapeutics Inc. | $3.21B | Mid cap | −2.71% | +79.06% |
| MBX | MBX Biosciences, Inc. | $3.22B | Mid cap | −2.71% | +366.53% |
| RCUS | Arcus Biosciences, Inc. | $3.92B | Mid cap | −2.57% | +191.29% |
| SLS | SELLAS Life Sciences Group, Inc. | $2.77B | Mid cap | −2.56% | +615.10% |
| GRFS | Grifols, S.A. | $5.38B | Mid cap | −2.35% | −19.39% |
| ORKA | Oruka Therapeutics, Inc. | $6.58B | Mid cap | −2.34% | +555.07% |
| DFTX | Definium Therapeutics, Inc. | $5.88B | Mid cap | −2.32% | +344.37% |
| REGN | Regeneron Pharmaceuticals, Inc. | $83.89B | Large cap | −2.25% | +39.36% |
| IMNM | Immunome, Inc. | $3.34B | Mid cap | −2.16% | +188.94% |
| ZBIO | Zenas BioPharma, Inc. | $2.15B | Mid cap | −2.16% | +97.73% |
| MRK | Merck & Co., Inc. | $377.72B | Mega cap | −2.14% | +86.85% |
| IDYA | IDEAYA Biosciences, Inc. | $4.01B | Mid cap | −2.12% | +66.32% |
| ABCL | AbCellera Biologics Inc. | $3.97B | Mid cap | −2.08% | +181.38% |
| HALO | Halozyme Therapeutics, Inc. | $12.41B | Large cap | −2.07% | +46.30% |
| MESO | Mesoblast Limited | $2.23B | Mid cap | −2.04% | +4.47% |
| AZN | AstraZeneca PLC | $263.12B | Mega cap | −2.00% | +5.09% |
| WRBY | Warby Parker Inc. | $3.15B | Mid cap | −2.00% | −3.96% |
| NUVB | Nuvation Bio Inc. | $2.44B | Mid cap | −1.97% | +135.93% |
| HTFL | Heartflow, Inc. | $4.26B | Mid cap | −1.90% | +40.79% |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.05B | Mid cap | −1.90% | +133.47% |
| PLSE | Pulse Biosciences, Inc. | $3.43B | Mid cap | −1.84% | +203.47% |
| CMPS | COMPASS Pathways plc | $2.02B | Mid cap | −1.81% | +209.53% |
| VCEL | Vericel Corporation | $2.17B | Mid cap | −1.80% | +18.25% |
| GMAB | Genmab A/S | $21.42B | Large cap | −1.78% | +36.20% |
| ABT | Abbott Laboratories | $198.74B | Large cap | −1.75% | −11.83% |
| MLYS | Mineralys Therapeutics, Inc. | $2.28B | Mid cap | −1.71% | +70.22% |
| PHG | Koninklijke Philips N.V. | $26.38B | Large cap | −1.60% | +1.27% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.
Micro and small cap listings are left out, so the list describes the market rather than thin trading, as are moves beyond 1,000% in a session, which are corporate actions the price series has not been restated for. This is a description of one day of price movement, nothing more. It says nothing about any company behind it.